HCN updates MDref for March

Health Communication Network (HCN) has released the March 2012 update for its MDref Drug Database for Medical Director 3.

The update is current from March 1 and will be delivered to subscribers via its automatic update service. Users can also download the update manually.

New drug monographs and products in the update include Jevtana (cabazitaxel), which was approved by the Therapeutic Goods Administration in December 2011 for the reatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

It also includes Revasc (desirudin), a subcutaneous, direct thrombin inhibitor approved for the prevention of venous thromboembolism after elective hip replacement; and Sequase (quetiapine fumarate ), an antipsychotic for treating schizophrenia and bipolar disorder.

HCN has also provided advice for users of PracSoft who want to add, edit, delete and reactivate MBS fees manually.

MBS fees are updated monthly and HCN bundles these up and makes them available for importing into PracSoft twice a year.

HCN has provided instructions on how to display those fees not shown by default, including new item numbers added by Medicare, made available before or after an HCN release.

PracSoft displays only those fees that are relevant to a primary care setting, which is not the entire MBS fee list.

Posted in Australian eHealth

You need to log in to post comments. If you don't have a Pulse+IT website account, click here to subscribe.

Sign up for Pulse+IT eNewsletters

Sign up for Pulse+IT website access

For more information, click here.

Copyright © 2021 Pulse+IT Communications Pty Ltd
No content published on this website can be reproduced by any person for any reason without the prior written permission of the publisher.
Supported by Social Media Agency | pepperit